How long Botox lasts and why it varies

Botulinum toxin works for months, not forever. Why the effect fades, which factors influence how long it lasts, and what the evidence says about common myths.

The short answer

For lines in the upper face, the effect of botulinum toxin type A typically lasts around three to four months in clinical trials, and many people experience three to five months in practice. In larger muscles such as the masseter, the effect often lasts somewhat longer. These are averages: the same dose can last noticeably longer in one person than in another.

Onset3 to 5 dFirst softening of muscle activity

Peak2 wksFull effect reached

Typical duration3 to 5 moUpper face, with individual variation

Why the effect wears off

Botulinum toxin cleaves a protein called SNAP-25 inside the nerve ending. Without it, the vesicles that carry acetylcholine cannot release their content, so the signal to contract does not reach the muscle. The nerve itself is not damaged. Over the following weeks, the nerve ending forms small new sprouts that temporarily take over signaling, and later the original nerve terminal recovers its function, after which the sprouts are withdrawn. Laboratory work by de Paiva and colleagues (PNAS, 1999) described this two-phase recovery. Once enough intact SNAP-25 is available again, muscle activity returns gradually, not overnight.

Factors that influence duration

Factor	What is known
Dose	In dose-ranging studies, higher doses produced a longer effect. A dose that is too low for a strong muscle wears off sooner.
Muscle strength and size	Stronger, larger muscles usually need more units for the same duration. This is one reason why men often need different doses (see Botox for men).
Treatment area	Small muscles that move constantly, such as those around the mouth, are usually treated with very low doses, so the effect can feel shorter there.
Product and preparation	Products differ in formulation and units are not interchangeable between brands. Correct storage and dilution matter.
Individual factors	Age, skin quality and how expressive a person is all play a role. Data on metabolism, sport or diet is limited.

Exercise and metabolism

The idea that intense exercise or a fast metabolism breaks down botulinum toxin faster is widespread, but there are no solid clinical data supporting it. The same applies to supplements marketed to make the effect last longer: the studies behind them are small and not confirmed. What is clear is that the first 24 hours matter for placement, which is why strenuous activity is avoided on the day of treatment. Our guide to the first Botox appointment covers the aftercare in detail.

Duration with regular treatment

Many experienced injectors observe that regular treatment can allow longer intervals or lower doses, because a muscle that has been relaxed for a long time tends to lose some bulk and strength. This is plausible and consistent with how muscles respond to reduced use, but it has not been proven in large controlled studies, and it does not happen for everyone.

Resistance to treatment

In rare cases the body forms neutralizing antibodies against botulinum toxin, after which treatments become less effective. A meta-analysis by Naumann and colleagues (Journal of Neural Transmission, 2013) found this to be uncommon overall and particularly rare at the low doses used in aesthetic medicine. Sensible practice is to use the lowest effective dose and to avoid very short intervals between treatments, which is why top-ups within a few weeks are generally avoided.

Planning your next treatment

There is no need to wait until all movement has returned. Many people plan their next appointment when they notice that lines become visible again with expression, typically after three to four months. A physician will adjust dose and interval to how your muscles responded last time. Whether, when and how often a treatment makes sense is a medical decision made in consultation.

References

Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46(6):840-849. PMID 12063480.
Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg. 2005;31(4):414-22; discussion 422. PMID 15871316.
Sun J, Wang L, Wu Y, et al. OnabotulinumtoxinA Treatment for Masseter Muscle Prominence: 6-Month Safety and Efficacy Results, Including Patient-Reported Outcomes, From a Phase 3, Randomized, Placebo-Controlled, Multiregional Trial. Aesthet Surg J. 2026;46(5):486-494. PMID 41092464.
Schlessinger J, Monheit G, Kane MA, et al. Time to onset of response of abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type A. Dermatol Surg. 2011;37(10):1434-1442. PMID 21745254.
Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol. 2006;13 Suppl 4:1-9. PMID 17112344.
de Paiva A, Meunier FA, Molgó J, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999;96(6):3200-3205. PMID 10077661.
Carruthers A, Carruthers J. Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg. 2005;31(10):1297-1303. PMID 16188182.
Field M, Splevins A, Picaut P, et al. AbobotulinumtoxinA (Dysport(®)), OnabotulinumtoxinA (Botox(®)), and IncobotulinumtoxinA (Xeomin(®)) Neurotoxin Content and Potential Implications for Duration of Response in Patients. Toxins (Basel). 2018;10(12). PMID 30551641.
Naumann M, Carruthers A, Carruthers J, et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov Disord. 2010;25(13):2211-2218. PMID 20737546.
Naumann M, Boo LM, Ackerman AH, et al. Immunogenicity of botulinum toxins. J Neural Transm (Vienna). 2013;120(2):275-290. PMID 23008029.